Respiratory Muscle Training in CF Patients

Respiratory Muscle Training in Patients With Cystic Fibrosis

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03190031

Acronym

MUCOMUREE

Enrollment

Registered

2017-06-16

Start date

2017-02-01

Completion date

2019-12-30

Last updated

2020-03-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cystic Fibrosis, Respiratory Muscles

Keywords

training, exercise, quality of life

Brief summary

The present study aims at evaluating the effect of respiratory muscle training in adult patients with cystic fibrosis on lung function, exercise performance and quality of life.

Interventions

OTHEREndurance respiratory muscle training

Training program of the respiratory muscles in endurance by using sustained isocapnic hyperpnea

OTHERResistance inspiratory muscle training

Training program of the inspiratory muscles in resistance by using repeated inspiratory maneuvers against a resistance

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Intervention model description

The patients will be randomized in 2 different groups, one being involved in an endurance respiratory muscle training program, the other being involved in resistance inspiratory muscle training.

Eligibility

Sex/Gender

ALL

Age

18 Years to 60 Years

Healthy volunteers

Inclusion criteria

* Patients with a clinical diagnosis of cystic fibrosis * Patients in steady state

Exclusion criteria

* Patients during exacerbation * Patients treated by oral corticotherapy (\>0.5 mg/kg/j during \>7 days) during the past 2 months * Pregnant patients

Design outcomes

Primary

Measure	Time frame	Description
Respiratory muscle endurance	Change from baseline (i.e. T0) measured immediately after the 8 weeks of intervention (T1)	Total breathing duration (in min) measured during an incremental hyperpnea test

Secondary

Measure	Time frame	Description
Respiratory muscle strength	Change from baseline (i.e. T0) measured immediately after the 8 weeks of intervention (T1)	Peak pressure (in mmHg) during maximal inspiratory and expiratory maneuvers
Maximal cycling performance	Change from baseline (i.e. T0) measured immediately after the 8 weeks of intervention (T1)	Peak maximal power output (in W) during an incremental cycling test
Quality of life of patients after the intervention	Change from baseline (i.e. T0) measured immediately after the 8 weeks of intervention (T1)	Score obtained during the questionnaire CQF14+

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026